Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+)

Detalles Bibliográficos
Autores principales:	Morgensztern, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Talbot, D, Ong, TJ
Formato:	Conference item
Lenguaje:	English
Publicado:	Elsevier 2018

Ejemplares similares

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+
por: Talbot, D, et al.
Publicado: (2018)

Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+
por: Govindan, R, et al.
Publicado: (2017)

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC)
por: Morgensztern, D, et al.
Publicado: (2017)

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)
por: Daniel Morgensztern, et al.
Publicado: (2021-02-01)

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer
por: Ponce Aix, S, et al.
Publicado: (2020)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
por: Morgensztern, D, et al.
Publicado: (2018)

nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC
por: Corey J. Langer, et al.
Publicado: (2018-07-01)

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis
por: Corey J. Langer, et al.
Publicado: (2021-01-01)

nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
por: Ajeet Gajra, et al.
Publicado: (2018-07-01)

nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy
por: Thomas M, et al.
Publicado: (2017-10-01)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2021-02-01)

nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial
por: Gridelli C, et al.
Publicado: (2018-05-01)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Julia Foldi, et al.
Publicado: (2022-02-01)

Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
por: Katsurada N, et al.
Publicado: (2020-02-01)

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma
por: Daniel J. Renouf, et al.
Publicado: (2022-08-01)

Chemotherapy in Metastatic NSCLC – New Regimens (Pemetrexed, nab-Paclitaxel)
por: Vera eHirsh, et al.
Publicado: (2014-07-01)

Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
por: Hiraku Kokubu, et al.
Publicado: (2023-05-01)

Erratum on: Chemotherapy in metastatic NSCLC – new regimens (pemetrexed, nab-paclitaxel)
por: Frontiers in Oncology Editorial Office
Publicado: (2014-10-01)

Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
por: Rui Wan, et al.
Publicado: (2023-06-01)

Macular Cystoid Edema Induced by Nab-Paclitaxel
por: Sara Alves Pereira, et al.
Publicado: (2022-04-01)

Successful Treatment of Advanced Thymic Carcinoma with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel: Two Case Reports
por: Tomoyuki Araya, et al.
Publicado: (2020-12-01)

Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
por: Zong Y, et al.
Publicado: (2020-12-01)

Efficacy and toxicity comparison of nab-paclitaxel plus S-1 and nab-paclitaxel plus gemcitabine as first-line chemotherapy for metastatic pancreatic cancer
por: Xi Guo, MD, et al.
Publicado: (2020-03-01)

First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report
por: Kunihiko Funaishi, et al.
Publicado: (2017-06-01)

Clinical efficacy of nab-paclitaxel in patients with metastatic pancreatic cancer
por: De Luca R, et al.
Publicado: (2018-06-01)

A Case of Stress Cardiomyopathy With Nab-Paclitaxel Infusion
por: Harjinder Singh MD, et al.
Publicado: (2023-11-01)

Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
por: Shuling Chen, et al.
Publicado: (2023-03-01)

QOL Evaluation of Nab-Paclitaxel and Docetaxel for Early Breast Cancer
por: Hiromi Okuyama, et al.
Publicado: (2018-10-01)

Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer
por: Prakash Vishnu, et al.
Publicado: (2011-04-01)

Clinical Characteristics and Risk Factors of Lung Injury Induced by Nab-Paclitaxel
por: Yoshioka K, et al.
Publicado: (2022-03-01)

Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study
por: Swapna Kochuveettil, et al.
Publicado: (2024-10-01)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Jane E. Rogers, et al.
Publicado: (2020-08-01)

The uses of anxiety: Grace Abounding to the Chief of Sinners (1666)
por: Seymour, L
Publicado: (2023)

Short Toxin-like Proteins Abound in Cnidaria Genomes
por: Michal Linial, et al.
Publicado: (2012-11-01)

Misperceptions of "light" cigarettes abound: National survey data
por: Thomson George, et al.
Publicado: (2009-05-01)

Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
por: Anne Steins, et al.
Publicado: (2017-01-01)

Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines
por: Lukas M. Braun, et al.
Publicado: (2020-05-01)

A case of metastatic NUT carcinoma with prolonged response on gemcitabine and nab‐paclitaxel
por: Shetal A. Patel, et al.
Publicado: (2021-08-01)

Factors affecting the efficacy of gemcitabine and nab-paclitaxel (paclitaxel + albumin) combination in the Russian patient population: results of a multicenter retrospective study
por: I. A. Pokataev, et al.
Publicado: (2019-12-01)

Bilateral macular edema secondary to nab-paclitaxel therapy for breast cancer
por: Zi-Yi Zhou, et al.
Publicado: (2024-10-01)